Greetings. Welcome to the SWK Holdings Fourth Quarter 2024 Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] Please note, this conference is being recorded. I will now turn the conference over to your host, Susan Xu, Investor Relations. You may begin.

Thank you. Good morning, everyone, and thank you for joining SWK Holdings' fourth quarter 2024 financial and corporate results call. Yesterday, SWK Holdings issued a press release detailing its financial results for the three months ended December 31, 2024. The press release can be found in the Investor Relations section of swkhold.com under News Releases. Before beginning today's call, I would like to make the following statement regarding forward-looking statements. Today, we will make certain forward-looking statements about future expectations, plans, events and circumstances, including statements about our strategy, future operations and our expectations regarding our capital allocation and cash resources. These statements are based on our current expectations, and you should not place undue reliance on these statements. Actual results may differ materially due to our risks and uncertainties, including those detailed in the Risks and Uncertainties Factors section of SWK Holdings' 10-K filed with the SEC and other filings we make with the SEC from time-to-time. SWK Holdings disclaims any obligation to update information contained in these forward-looking statements, whether as a result of new information, future events or otherwise. Joining me from SWK Holdings on today's call is Jody Staggs, President and CEO; and Adam Rice, CFO, who will provide an update on SWK fourth quarter 2024 corporate and financial results. Jody, go ahead.

Thank you, Susan, and thanks, everyone for joining our fourth quarter conference call. We are pleased with SWK's fourth quarter performance, and the company enters 2025 on solid footing. Our fourth quarter was highlighted by solid financial performance, including $8.2 million of finance segment net income, improvement in the portfolio's credit quality and $44 million of capital deployed into yielding finance receivables to life science companies. Our non-GAAP tangible financing book value per share increased 8% year-over-year to $21.15 and with shares trading at a discount to book, and given our excess capital, we have been active purchasers of our shares having repurchased approximately 100,000 shares for $1.6 million since September 30, 2024. During the fourth quarter, we closed an up to $8 million senior secured term loan to Triple Ring Technologies, upsized the loan to $30 million and advanced a cumulative $10.6 million to four performing borrowers. In January, we closed an up to $15 million term loan with Impedimed with $10 million advanced at close. These are all core SWK financings to commercial stage life science companies. Each is either public and has demonstrated the ability to raise capital or private with the supportive sponsor. Since we last spoke, three SWK finance receivables were repaid at premiums to the GAAP carrying value. In December, Veru made a $4.2 million payment to fully satisfy the FC2 royalty. The FC2 royalty generated a 45% IRR and a 2.7x MOIC. In December, MolecuLight made a final payment totaling $12.2 million to repay its term loan to SWK. The MolecuLight term loan (ph) generated a 20% IRR and a 1.6x MOIC. SWK continues to hold equity in MolecuLight, which is carried at zero on our books. In March, ANI Pharma made a $17.25 million payment to exercise an option to buy out…

Thank you, Jody, and good morning, everyone. Yesterday, we reported earnings for the fourth quarter of 2024. We reported GAAP pretax net income of $8.6 million, or $0.70 per diluted share. Our reported fourth quarter 2024 net income of $5.9 million after income tax expense of $2.7 million, included a $1.1 million increase in Finance Receivables segment revenue, and a $1.3 million increase in Pharmaceutical Development segment revenue. The $1.1 million increase in revenue -- or in year-over-year Finance Receivables segment revenue was primarily due to a $2.3 million increase in interest and fees earned on newly funded loans and royalties. The accelerated fees on early payoffs -- and accelerated fees on early payoffs, the increase in Finance Receivables segment revenue was partially offset by $900,000 as a result of two investments entering non-accrual status this year. As of December 31, 2024, our GAAP book value per share was $23.45, a 5% increase compared to $22.33 as of December 31, 2023. Additionally, non-GAAP tangible finance book value per share totaled $21.15 as of December 31, 2024, and 8.3% increase compared to $19.53 as of December 31, 2023. Overall operating expenses -- which overall operating expenses, which include interest expense, pharmaceutical manufacturing, research and development expense, general and administrative expense, and provision for credit losses were $6.6 million during fourth quarter 2024, compared to $6.8 million in fourth quarter 2023. MOD3 operating expenses were $1.6 million in fourth quarter 2024 compared to $1.8 million in fourth quarter 2023, and Finance Receivables segment operating expenses were $5.3 million in the fourth quarter 2024 compared to $5.6 million in fourth quarter 2023. The Finance Receivable operating segment expenses further breakdown for fourth quarter 2024 to general and administrative expenses of $2.1 million, provision for credit losses of $2 million and interest expense of $1.2 million, and for fourth quarter 2023, general and administrative expenses of $2.1 million, provision for credit losses of $2.4 million and interest expense of $1.1 million. The decrease in Finance Receivables segment operating expenses was mainly due to a $400,000 decrease in provision for credit losses. The decrease in provision for credit losses is most notably attributed to the strategic exit of three non-accrual investments during the quarter. Turning to our share repurchase program. We bought back roughly 50,000 shares at a total cost of $800,000 during the quarter. Since quarter close, we have repurchased an additional 47,000 shares for a total cost of $800,000. Lastly, for financial reporting purposes, we have transitioned the MOD3 segment to held for sale, as of December 31, 2024. The transition to held for sale status was based on criteria set forth in GAAP accounting guidance and is related to the option purchase agreement entered into between MOD3 and a strategic partner effective January 1, 2024. With that, I'll turn it back over to Jody.

Thank you, Adam. We entered 2025 with a healthy loan portfolio yielding in the mid-teens as well as $30 million of gross cash. The sale of our remaining, performing royalty portfolio and closeout of the FX hedge will add an additional $39 million of cash to our balance sheet, and we anticipate declaring a dividend on the closing of the final royalty transaction. Our MOD3 CDMO division is self-sufficient in working with our strategic partner to address the sizable need for Phase I and Phase II nasal CDMO services. With that, let's open the call to questions.

Absolutely. At this time, we will be conducting a question-and-answer session. [Operator Instructions] The first question comes from Scott Jensen, Private Investor. Please proceed.

Hi. Good morning, Jody and team. Congratulations on so much progress since we last spoke.

Thank you.

I got a couple of questions for you. When you're thinking about a dividend, since it's such a large pile of cash, are you thinking about ongoing dividend or a special dividend, returning some of that cash, that cash pile to shareholders?

Yeah, Scott. Thanks. So the Board is still considering our options. I would anticipate initially a one-time special dividend, that doesn't mean that there might not be additional special dividends in the future. But at this time, I don't anticipate a recurring dividend.

Yeah. Love it. That's what I would hope for as well. Second, as far as the buyback, where are you on the current buyback? And then again, if that could be something the Board is going to consider about renewing or increasing the buyback?

Yeah. And Adam, if you have the e-mail pulled up, I might -- from Courtney, I might have you look and check how much room we have. But we do have room -- enough room on our buyback. It's been interesting trying to navigate this with our blackout period. So once we go into the blackout period, the algorithm takes over, and we don't really have control over how many shares are repurchased. When we're not in the blackout period, we can direct it and be more aggressive or less aggressive. So I would say, we're still active repurchasers of our shares. We think particularly with the news we announced today, shares are trading at a 20% discount, that's an attractive use of capital. So we'll continue to do that. We should be out of the blackout period when we report first quarter roughly May 15, in that ballpark and the program will expire. I think it expires roughly that date. I don't -- we have not discussed it, but I think the Board views the buyback as an attractive use of capital. And I would expect, assuming everything else is equal, that the Board would strongly consider reauthorizing the program for another year.

Excellent. Thank you. And I just also want to say congratulations on all those workouts BIOLASE, etc. Those were excellent and cleaning it up.

Thank you, Scott.

I’ll get out of the queue and see if somebody else, but keep up the good work and thank you, again. And love reading the progress.

Thank you. Appreciate the support.

[Operator Instructions] Okay. We have no further questions in the queue. I would like to turn the floor back to Jody for any closing remarks.

Thanks, John. Thank you for joining us today and for your continued support of SWK. We hope everyone has a great day. Thanks.

This concludes today's conference, and you may disconnect your lines at this time. Thank you for your participation.